Here's one for Alex and Pete. Believe it or not, this is actually a good investment. It is what has propelled the American Heritage fund to top place in the last few months. Heiko Thieme, the manager, thinks this company is going much higher, once product approval occurs.
NEW YORK, Sept. 18 /PRNewswire/ -- Senetek PLC (NASDAQ:
SNTKY) announced today that it has filed three additional Product Licensing Applications (PLAs) with the appropriate regulatory agencies seeking approval to market in Switzerland, South Africa and New Zealand its new drug therapy for treating moderate-to-severe, organic-based erectile dysfunction (ED) in males -- INVICORP(TM), a unique combination therapy administered with a proprietary
state-of-the-art autoinjector.
In April of this year, Senetek announced that it had filed its first PLA -- with England's Medicines Control Agency (MCA) -- for approval to market INVICORP. In addition, in July, Senetek announced it had filed its second and third PLAs with the appropriate regulatory authorities in Denmark and Ireland.
These submission are a part of the Company's pan-European approval strategy for INVICORP. INVICORP is an injectable formulation of vasoactive intestinal polypeptide (VIP) in combination with phentolamine mesylate. Efficacy of greater than 80 percent has been reported from multiple sites, and the placebo-controlled study was highly statistically significant. Discontinuation for adverse events has been reported only in 12 patients (1.7 percent). A novel autoinjector has been developed for use with INVICORP. The device is small (5.75" x 0.50"), utilizes an ultrafine 29-gauge needle that is not visible to the patient prior to injection, and contains a single dose of INVICORP. Senetek PLC is a biotechnology company providing solutions for aging-related health problems.
Visit Senetek's Web site on the Internet senetekplc.com
Happy Investing!
Vanni |
